WO2004011490A1 - A immounlogical epitope of the hiv strain type o and the uses thereof - Google Patents
A immounlogical epitope of the hiv strain type o and the uses thereof Download PDFInfo
- Publication number
- WO2004011490A1 WO2004011490A1 PCT/CN2002/000552 CN0200552W WO2004011490A1 WO 2004011490 A1 WO2004011490 A1 WO 2004011490A1 CN 0200552 W CN0200552 W CN 0200552W WO 2004011490 A1 WO2004011490 A1 WO 2004011490A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epitope
- hiv
- strain
- amino acid
- immunological epitope
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 22
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 17
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 4
- 239000004220 glutamic acid Substances 0.000 claims abstract description 4
- 230000001900 immune effect Effects 0.000 claims description 16
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009352 congenital transmission Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- -1 succinimide ester Chemical class 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the invention relates to an immunological epitope of HIV type 0 strain and its application.
- HIV-1 caused by an immune disease, there is no effective cure for complete cure, and no vaccine can prevent it.
- the high variability of immunodeficiency viruses has been a challenge in the design of HIV vaccines and drugs.
- HIV-1 membrane protein gpl60 precursor protein of membrane protein gpl20 and transmembrane protein gp41
- antibodies can inhibit mucosal transmission of HIV-1 virus and mother-to-child transmission, and can clear HIV-1 virus in the blood (Nature Medicine 1999, 5: 204; Nature Medicine 2000, 6: 200; Nature Medicine 1999, 5: 211);
- the epitope-specific monoclonal antibody to the primary neutralizing epitope ELDKWA on the transmembrane protein g p41 of human immunodeficiency virus (HIV-1) can inhibit in vitro Multiple HIV-1 strains infect target cells (J. Virology 1993, 67: 6642; AIDS Res. Human Retroviruses 1994, 10: 1651; AIDS 1996, 10: 587).
- HIV-1 can escape the neutralization of neutralizing antibodies by restricting mutations in neutralizing epitopes (Immunity 10, 431-438, 1999).
- ELDKWA is recognized as an important HIV-1 neutralizing epitope. This epitope is highly conserved, but certain restrictive mutations at the D or K site can make the virus escape the neutralizing effect of monoclonal antibodies.
- the object of the present invention is to provide a new immunological epitope of HIV type 0 strain.
- An immunological epitope of HIV type 0 strain includes two adjacent amino acid residues whose nitrogen terminus is aspartic acid and whose carbon terminus is glutamic acid.
- the amino acid residue usually connected at the nitrogen end of the immunological epitope is leucine; the amino acid residue usually connected at the carbon end is tryptophan, and the amino acid residue sequence of the immunological epitope is LDEW.
- the amino acid residue linked to the nitrogen terminal is usually glutamic acid, and the amino acid residue linked to the carbon terminal is alanine.
- the amino acid residue sequence of the immunological epitope is ELDEWA.
- the inventor's search of the HIV database found that the transmembrane protein gp41 of all HIV-1 virus type 0 strains carries the ELDEWA epitope (as shown in Table '1), However, other HIV-1 virus subtypes do not carry this epitope, further confirming that ELDEWA is a unique epitope of HIV-1 virus type 0 strain, which can be used as a target site for the identification and diagnosis of HIV-1 virus type 0 strain. As a target site for therapeutic drugs.
- Table 1 Characteristic ELDEWA epitopes of HIV-1 virus type 0 strain
- a second object of the present invention is to provide a monoclonal antibody capable of specifically binding to an immunological epitope of the HIV type 0 strain of the present invention.
- Monoclonal mouse hybridoma cell line 14D9 murine monoclonal antibody 14D9 subtype: IgG1).
- the mouse hybridoma cell line 14D9 was deposited on June 27, 2002 at the General Microbial Center of the China Microbial Species Collection Management Committee (CGMCC for short), and the accession number is CGMCC Na 0753. ⁇
- the monoclonal antibody 14D9 produced by the mouse hybridoma cell line 14D9 can specifically recognize the ELDEWA-epitope specific to the transmembrane protein gp41 of HIV-1 virus type 0 strain, and does not recognize the ELDKWA carried by other HIV-1 virus subtypes. ELNKWA- and ELEKWA- epitopes.
- Figure 1 is an electrophoresis image of a monoclonal antibody of the present invention after reaction with a recombinant, soluble gp41 fusion protein with different epitopes.
- An epitope polypeptide containing an ELDEWA-epitope specific to the transmembrane protein gp41 of HIV-1 0 strain was artificially synthesized.
- the epitope polypeptide contains 4 repeated ELDEWA-immunological epitopes, and the amino acid residue sequence is: CELDEWAGELDEWAGELDEWAGELDEWA;
- He'J used MBS (nrmaleimidobenzoyHHiydroxy succinimide ester) to couple the epitope polypeptide with the carrier protein BSA;
- Example 2 Specific identification of the ELDEWA-epitope of HIV-1 virus type 0 strain by the antibody of the present invention
- the monoclonal antibody secreted by the hybridoma cell line 14D9 was subjected to an incubation reaction with recombinant, soluble gp41 fusion proteins with different epitopes.
- the results are shown in Figure 1. From the results in the figure, it can be seen that the hybridoma cell line 14D9 secreted
- the monoclonal antibody specifically recognizes the ELDEWA-epitope of HIV-1 virus type 0 strain.
- A molecular weight protein
- B the monoclonal antibody of the present invention recognizes rsgp41 (GST-rsgp41) with the ELDEWA epitope.
- ELDE wA 42KD]
- C The monoclonal antibody of the present invention does not recognize rsgp41 (GST—rsgp41 EL
- D The monoclonal antibody of the present invention does not recognize GST
- E The monoclonal antibody of the present invention recognizes an ELDEWA epitope GST- ELDEWA (26KD) '.
- ELDEWA is a unique epitope of HIV-1 virus type 0 strain. It can be used as a target site for the identification and diagnosis of HIV-1 virus type 0 strain, and can also be used as a target site for therapeutic drugs.
- the monoclonal antibody of the present invention will be widely used in identifying and diagnosing HIV-1 virus type 0 strain and preparing passive immune drugs for infection of HIV-1 type 0 strain. Drugs using the monoclonal antibody of the present invention as an active ingredient can be widely used. Hope to be applied in the treatment of AIDS.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a new immounlogical epitope of the HIV strain Type O and the uses thereof. The present invention provides a new immounlogical epitope of the HIV strain Type O. The N-end of the epitope is asparagine, its C-end is two adjacent residues of glutamic acid. The N-end of the epitope being consist of two amino acid residues usually links with the leucine residue. The C-end of the epitope usually ligates to the tryptophan residue. The amino acid sequence of the immounlogical epitope is LDEW. Based on the sequence, the N-end of it usually ligates to the glutamic acid residue. The C-end of it usually links with the alanine residue, So the amino acid sequence of the immounlogical epitope is ELDEWA. The epitope can be used as target for the identification and diagnosis of the HIV-1 Type O, also as target for drugs.
Description
艾滋病病毒 0型株的一个免疫学表位及其应用 技术领域 An immunological epitope of HIV type 0 strain and its application
本发明涉及艾滋病病毒 0型株的一个免疫学表位及其应用。 The invention relates to an immunological epitope of HIV type 0 strain and its application.
背景技术 Background technique
获得性免疫缺陷综合症， 又称艾滋病， 是由人类免疫缺陷病毒 I型 Acquired Immunodeficiency Syndrome, also known as AIDS, is caused by human immunodeficiency virus type I
( HIV-1 ) 引起的一种免疫性疾病， 目前尚无彻底治愈的有效药物， 也没有 疫苗可以预防。 免疫缺陷病毒的高变异性一直是 HIV疫苗和药物设计中的 难题。 (HIV-1) caused by an immune disease, there is no effective cure for complete cure, and no vaccine can prevent it. The high variability of immunodeficiency viruses has been a challenge in the design of HIV vaccines and drugs.
最近国外抗艾滋病药物临床研究结果证明， 在被动免疫治疗中， 组合 使用针对 HIV- 1 膜蛋白 gpl60 (膜蛋白 gpl20及跨膜蛋白 gp41的前体蛋白） 上 的几个特定中和表位的中和抗体 (其中包括 ELDKWA表位特异性的单克隆抗体 2F5) ,能抑制 HIV— 1病毒的粘膜传染以及母婴传播,并能清除血液中的 HIV— 1 病毒（Nature Medicine 1999， 5 : 204 ; Nature Medicine 2000， 6 : 200 ; Nature Medicine 1999， 5 : 211)； 人免疫缺陷病毒（HIV- 1)跨膜蛋白 gp41 上的主要中和表位 ELDKWA的表位特异性单克隆抗体能够体外抑制多种 HIV— 1 病毒株感染靶细胞 （J. Virology 1993, 67 : 6642 ; AIDS Res. Human Retroviruses 1994, 10 : 1651 ; AIDS 1996， 10 : 587 ) 。 研究证明， HIV-1 能够通过中和表位的限制性变异逃脱中和抗体的中和作用 （Immunity 10， 431-438, 1999 ) 。 ELDKWA是公认的重要的 HIV- 1中和表位， 该表位的保守 性很强， 但在 D或 K位点的某些限制性变异， 能够使病毒逃脱单抗的中和作 用。 Recent clinical studies of anti-AIDS drugs abroad have proved that in passive immunotherapy, a combination of several specific neutralizing epitopes on HIV-1 membrane protein gpl60 (precursor protein of membrane protein gpl20 and transmembrane protein gp41) is used in combination. And antibodies (including the monoclonal antibody 2F5 specific to the ELDKWA epitope), can inhibit mucosal transmission of HIV-1 virus and mother-to-child transmission, and can clear HIV-1 virus in the blood (Nature Medicine 1999, 5: 204; Nature Medicine 2000, 6: 200; Nature Medicine 1999, 5: 211); The epitope-specific monoclonal antibody to the primary neutralizing epitope ELDKWA on the transmembrane protein g p41 of human immunodeficiency virus (HIV-1) can inhibit in vitro Multiple HIV-1 strains infect target cells (J. Virology 1993, 67: 6642; AIDS Res. Human Retroviruses 1994, 10: 1651; AIDS 1996, 10: 587). Studies have shown that HIV-1 can escape the neutralization of neutralizing antibodies by restricting mutations in neutralizing epitopes (Immunity 10, 431-438, 1999). ELDKWA is recognized as an important HIV-1 neutralizing epitope. This epitope is highly conserved, but certain restrictive mutations at the D or K site can make the virus escape the neutralizing effect of monoclonal antibodies.
发明公开 Invention Disclosure
本发明的目的是提供艾滋病病毒 0型株的一个新的免疫学表位。 The object of the present invention is to provide a new immunological epitope of HIV type 0 strain.
艾滋病病毒 0型株的一个免疫学表位， 包括氮末端为天门冬氨酸， 碳末 端为谷氨酸的两个相邻氨基酸残基。 An immunological epitope of HIV type 0 strain includes two adjacent amino acid residues whose nitrogen terminus is aspartic acid and whose carbon terminus is glutamic acid.
所述免疫学表位的氮端通常连接的氨基酸残基为亮氨酸； 碳端通常连接 的氨基酸残基为色氨酸， 这时该免疫学表位的氨基酸残基序列为 LDEW。 在
该序列的基础上， 通常氮端连接的氨基酸残基为谷氨酸， 碳端连接的氨基酸 残基为丙氨酸， 这时该免疫学表位的氨基酸残基序列为 ELDEWA。 The amino acid residue usually connected at the nitrogen end of the immunological epitope is leucine; the amino acid residue usually connected at the carbon end is tryptophan, and the amino acid residue sequence of the immunological epitope is LDEW. In Based on this sequence, the amino acid residue linked to the nitrogen terminal is usually glutamic acid, and the amino acid residue linked to the carbon terminal is alanine. At this time, the amino acid residue sequence of the immunological epitope is ELDEWA.
发明人通过对 HIV数据库 (http：〃 hiv-web. lanl. gov)的检索发现， 所 有 HIV- 1 病毒 0 型株的跨膜蛋白 gp41 均带有 ELDEWA表位 （如表 ' 1 所 示） ， 而其它 HIV-1病毒亚型不带有此表位， 进一步证实 ELDEWA是 HIV - 1 病毒 0型株的特有表位， 可用于 HIV- 1病毒 0型株鉴别和诊断的靶位点， 也 可以作为治疗药物的靶位点。 The inventor's search of the HIV database (http: 〃 hiv-web. Lanl. Gov) found that the transmembrane protein gp41 of all HIV-1 virus type 0 strains carries the ELDEWA epitope (as shown in Table '1), However, other HIV-1 virus subtypes do not carry this epitope, further confirming that ELDEWA is a unique epitope of HIV-1 virus type 0 strain, which can be used as a target site for the identification and diagnosis of HIV-1 virus type 0 strain. As a target site for therapeutic drugs.
表 1： HIV-1 病毒 0型株带有特征性的 ELDEWA表位 Table 1: Characteristic ELDEWA epitopes of HIV-1 virus type 0 strain
小鼠杂交瘤细胞系 14D9 已于 2002年 06月 27 日保藏于中国微生物菌 种保藏管理委员会普通微生物中心 （简称 CGMCC ) ， 保藏号为 CGMCC Na 0753 ο The mouse hybridoma cell line 14D9 was deposited on June 27, 2002 at the General Microbial Center of the China Microbial Species Collection Management Committee (CGMCC for short), and the accession number is CGMCC Na 0753. ο
小鼠杂交瘤细胞系 14D9产生的单克隆抗体 14D9能够特异性识别 HIV - 1 病毒 0型株跨膜蛋白 gp41特有的 ELDEWA-表位， 而不识别其它 HIV- 1病毒 亚型所携带 ELDKWA -、 ELNKWA- 和 ELEKWA-表位。 The monoclonal antibody 14D9 produced by the mouse hybridoma cell line 14D9 can specifically recognize the ELDEWA-epitope specific to the transmembrane protein gp41 of HIV-1 virus type 0 strain, and does not recognize the ELDKWA carried by other HIV-1 virus subtypes. ELNKWA- and ELEKWA- epitopes.
下面结合具体实施例对本发明做进一步说明。 The present invention is further described below with reference to specific embodiments.
附图说明 BRIEF DESCRIPTION OF THE DRAWINGS
图 1为本发明单克隆抗体与带有不同表位的重组、 可溶性 gp41融合蛋白 反应后的电泳图。 Figure 1 is an electrophoresis image of a monoclonal antibody of the present invention after reaction with a recombinant, soluble gp41 fusion protein with different epitopes.
实施发明的最佳方式 The best way to implement the invention
实施例 1、 鼠类来源的杂交瘤细胞系 14D9的制备过程： Example 1. Preparation process of murine-derived hybridoma cell line 14D9:
1、 人工合成一条含有 HIV- 1 0型株跨膜蛋白 gp41特有的 ELDEWA-表位的 表位多肽， 该表位多肽含有 4次重复的 ELDEWA-免疫学表位， 其氨基酸残基序 列为： CELDEWAGELDEWAGELDEWAGELDEWA; 1. An epitope polypeptide containing an ELDEWA-epitope specific to the transmembrane protein gp41 of HIV-1 0 strain was artificially synthesized. The epitope polypeptide contains 4 repeated ELDEWA-immunological epitopes, and the amino acid residue sequence is: CELDEWAGELDEWAGELDEWAGELDEWA;
2、 禾 'J用 MBS (nrmaleimidobenzoyHHiydroxy succinimide ester)将上述表位 多肽与载体蛋白 BSA耦联； 2. He'J used MBS (nrmaleimidobenzoyHHiydroxy succinimide ester) to couple the epitope polypeptide with the carrier protein BSA;
3、 将上述耦联物与福氏佐剂混合 （两种物质的重量比为， 耦联物： 福 氏佐剂 = 1 : 1 ) 免疫 Balb/c小鼠， 每两周免疫一次。 首次使用完全福氏佐 剂， 以后使用不完全福氏佐剂。 每次免疫抗原剂量为： 含 10微克表位多肽的 耦联物 /次 /只， 共免疫 3次； 3. Mix the above conjugate with Freund's adjuvant (the weight ratio of the two substances is: conjugate: Freund's adjuvant = 1: 1). Immunize Balb / c mice every two weeks. Full Freund's adjuvant was used for the first time and incomplete Freund's adjuvant was used afterwards. The dose of each immunized antigen is: conjugates containing 10 micrograms of epitope polypeptide / times / only, a total of 3 immunizations;
4、 将免疫后的小鼠脾细胞与小鼠骨髓瘤细胞采用常规细胞融合技术融 合， 并制备杂交瘤， 从杂交瘤细胞中筛选出能分泌 ELDEWA-表位特异性单克 隆抗体的杂交瘤； 4. Fusion the mouse spleen cells and mouse myeloma cells with conventional cell fusion technology, and prepare hybridomas, and select hybridomas that can secrete ELDEWA-epitope-specific monoclonal antibodies from the hybridoma cells;
5、 克隆杂交瘤， 获得能分泌 ELDEWA-表位特异性单克隆抗体的克隆杂交
瘤细胞系 14D9。 5. Cloning hybridomas to obtain clones capable of secreting ELDEWA-epitope-specific monoclonal antibodies Tumor cell line 14D9.
实施例 2、 本发明抗体对 HIV- 1病毒 0型株 ELDEWA-表位的特异性识 别 Example 2. Specific identification of the ELDEWA-epitope of HIV-1 virus type 0 strain by the antibody of the present invention
将杂交瘤细胞系 14D9分泌的单克隆抗体与带有不同表位的重组、 可溶性 gp41 融合蛋白进行温浴反应， 结果如图 1所示， 从图中的结果可以看出， 杂交瘤 细胞系 14D9分泌的单克隆抗体对 HIV-1病毒 0型株 ELDEWA-表位具有特异性识 另 lj， 图中， A: 分子量蛋白； B: 本发明单克隆抗体识别带有 ELDEWA表位的 rsgp41 (GST - rsgp41ELDEwA) 42KD〕 C : 本发明单克隆抗体不识别带有 ELDKWA表位的 rsgp41 (GST— rsgp41EL D : 本发明单克隆抗体不识别 GST; E: 本发明单克隆抗体识别含有 ELDEWA表位的 GST- ELDEWA (26KD) '。 工业应用 The monoclonal antibody secreted by the hybridoma cell line 14D9 was subjected to an incubation reaction with recombinant, soluble gp41 fusion proteins with different epitopes. The results are shown in Figure 1. From the results in the figure, it can be seen that the hybridoma cell line 14D9 secreted The monoclonal antibody specifically recognizes the ELDEWA-epitope of HIV-1 virus type 0 strain. In the figure, A: molecular weight protein; B: the monoclonal antibody of the present invention recognizes rsgp41 (GST-rsgp41) with the ELDEWA epitope. ELDE wA) 42KD] C: The monoclonal antibody of the present invention does not recognize rsgp41 (GST—rsgp41 EL D: The monoclonal antibody of the present invention does not recognize GST; E: The monoclonal antibody of the present invention recognizes an ELDEWA epitope GST- ELDEWA (26KD) '. Industrial applications
ELDEWA是 HIV- 1病毒 0型株的特有表位， 可用于 HIV- 1病毒 0型株鉴 别和诊断的靶位点， 也可以作为治疗药物的靶位点。 本发明的单克隆抗体在 鉴别、 诊断 HIV- 1病毒 0型株、 制备用于 HIV- 1 0型毒株感染被动免疫药物 中将得到广泛应用， 以本发明单克隆抗体为活性成份的药物可望在治疗艾滋 病中得到应用。
ELDEWA is a unique epitope of HIV-1 virus type 0 strain. It can be used as a target site for the identification and diagnosis of HIV-1 virus type 0 strain, and can also be used as a target site for therapeutic drugs. The monoclonal antibody of the present invention will be widely used in identifying and diagnosing HIV-1 virus type 0 strain and preparing passive immune drugs for infection of HIV-1 type 0 strain. Drugs using the monoclonal antibody of the present invention as an active ingredient can be widely used. Hope to be applied in the treatment of AIDS.
关于微生物保藏的说明 Notes on microbial deposits
(细则 13之二） (Rule 13bis)
由受理局填写 由国际局填写 S本! «已经和国际申请一起收入到 □本页己经和国际申请一起收入到 受权官员 受权官员 Completed by the receiving Office Completed by the International Bureau S! «Already included with the international application □ This page has been included with the international application to the authorized official Authorized official
PCT/R0134表 (1992年 7月）
Form PCT / R0134 (July 1992)
Claims
1、 艾滋病病毒 0型株的一个免疫学表位,包括氮末端为天门冬氨酸， 碳末端为谷氨酸的两个相邻氨基酸残基。 1. An immunological epitope of HIV type 0 strain, which includes two adjacent amino acid residues whose nitrogen end is aspartic acid and whose carbon end is glutamic acid.
2、 根据权利要求 1所述的艾滋病病毒 0型株的一个免疫学表位， 其特 征在于： 所述免疫学表位的氨基酸残基序列为 LDEW。 2. An immunological epitope of the HIV type 0 strain according to claim 1, characterized in that the amino acid residue sequence of the immunological epitope is LDEW.
3、 根据权利要求 2所述的艾滋病病毒 0型株的一个免疫学表位， 其特 征在于： 所述免疫学表位的氨基酸残基序列为 ELDEWA。 3. An immunological epitope of the HIV type 0 strain according to claim 2, characterized in that the amino acid residue sequence of the immunological epitope is ELDEWA.
4、 与权利要求 1一 3中任意一项所述艾滋病病毒 0型株的免疫学表位专 一结合的单克隆抗体。 4. A monoclonal antibody that specifically binds to an immunological epitope of an HIV type 0 strain according to any one of claims 1 to 3.
5、 由保藏号为 CGMCC ΝΩ0753的杂交瘤细胞系 14D9产生的与艾滋病病 毒 0型株抗原专一结合的单克隆抗体。 5. Monoclonal antibody specifically produced by the hybridoma cell line 14D9 deposited under the accession number CGMCC No. 0753, which specifically binds to the HIV type 0 strain antigen.
6、 鼠类来源的杂交瘤细胞系 14D9， CGMCC Na0753。 6. Murine-derived hybridoma cell line 14D9, CGMCC Na0753.
7、 权利要求 1一 3中任意一项所述的免疫学表位在鉴别、 诊断 HIV- 1病 毒 0型株中的应用。 7. The use of the immunological epitope according to any one of claims 1 to 3 in identifying and diagnosing HIV-1 virus type 0 strain.
8、 权利要求 1一 3中任意一项所述的免疫学表位作为治疗药物靶位点的 应用。 8. Use of the immunological epitope according to any one of claims 1 to 3 as a target site for a therapeutic drug.
5
5
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002325467A AU2002325467A1 (en) | 2002-07-29 | 2002-08-09 | A immounlogical epitope of the hiv strain type o and the uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021253730A CN1472314A (en) | 2002-07-29 | 2002-07-29 | Immunity expression of AIDS virus O and its use |
| CN02125373.0 | 2002-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004011490A1 true WO2004011490A1 (en) | 2004-02-05 |
Family
ID=30121235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2002/000552 WO2004011490A1 (en) | 2002-07-29 | 2002-08-09 | A immounlogical epitope of the hiv strain type o and the uses thereof |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1472314A (en) |
| AU (1) | AU2002325467A1 (en) |
| WO (1) | WO2004011490A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991013909A1 (en) * | 1990-03-15 | 1991-09-19 | Proteus Molecular Design Limited | Synthetic polypeptides |
| EP0492560A2 (en) * | 1990-12-26 | 1992-07-01 | Joseph P. Cotropia | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides |
| WO1994029339A1 (en) * | 1993-06-09 | 1994-12-22 | Connaught Laboratories Limited | Tandem synthetic hiv-1 peptides |
-
2002
- 2002-07-29 CN CNA021253730A patent/CN1472314A/en active Pending
- 2002-08-09 AU AU2002325467A patent/AU2002325467A1/en not_active Abandoned
- 2002-08-09 WO PCT/CN2002/000552 patent/WO2004011490A1/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991013909A1 (en) * | 1990-03-15 | 1991-09-19 | Proteus Molecular Design Limited | Synthetic polypeptides |
| EP0492560A2 (en) * | 1990-12-26 | 1992-07-01 | Joseph P. Cotropia | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides |
| WO1994029339A1 (en) * | 1993-06-09 | 1994-12-22 | Connaught Laboratories Limited | Tandem synthetic hiv-1 peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002325467A8 (en) | 2004-02-16 |
| CN1472314A (en) | 2004-02-04 |
| AU2002325467A1 (en) | 2004-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE49037E1 (en) | Broadly neutralizing antibody and uses thereof | |
| EP0570357A2 (en) | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates | |
| EP2788026A2 (en) | V1v2 immunogens | |
| Pantophlet et al. | Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity | |
| Tong et al. | Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques | |
| Qin et al. | Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence | |
| Gorny et al. | Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins | |
| Pinter | Roles of HIV-1 Env variable regions in viral neutralization and vaccine development | |
| JPH05503851A (en) | Neutralizing and/or ADCC Mediating Monoclonal HIV Antibodies | |
| Simonich et al. | A diverse collection of B cells responded to HIV infection in infant BG505 | |
| Visciano et al. | In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120 | |
| Zhang et al. | Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency | |
| US20150238594A1 (en) | Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof | |
| Gao et al. | Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins | |
| Dorgham et al. | Reverse immunology approach to define a new HIV-gp41-Neutralizing epitope | |
| AU2017251715A1 (en) | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof | |
| US11124561B2 (en) | Broadly cross-reactive HIV-1-specific antibodies for prevention and treatment of HIV | |
| WO2004011490A1 (en) | A immounlogical epitope of the hiv strain type o and the uses thereof | |
| WO2004011633A1 (en) | The antibody directed against the hiv strain type o, the hybridoma cell line producing it and the uses thereof | |
| Zhang et al. | Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies | |
| Quinnan Jr et al. | Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins | |
| WO2002032452A1 (en) | Composition for aids and method producing it | |
| Nduati et al. | A diverse collection of B cells responded to HIV infection in infant BG505. | |
| US10660951B2 (en) | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof | |
| Vaine et al. | Improved induction of antibodies against key neutralizing epitopes by HIV-1 gp120 DNA prime-protein boost vaccination compared to gp120 protein only vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |